Bundibugyo ebolavirus

Bundibugyo ebolavirus is one of six recognised species in the genus Orthoebolavirus (formerly Ebolavirus). It was first identified in 2007 during an outbreak in Bundibugyo District, western Uganda, which produced 131 cases and 39 deaths. A second outbreak occurred in 2012 in Isiro, eastern DRC, with 38 cases and 13 deaths. Before the 2026 Ituri outbreak both events were the entire clinical record for this species: fewer combined cases than a single bad week of the 2014-16 West Africa epidemic.

The virus belongs to the Filovirus family alongside Marburg virus. Like all Ebola species it targets endothelial cells and immune cells, causing haemorrhagic fever with a case-fatality rate estimated at 30 to 40 per cent in lab-confirmed cases (Imperial College London, May 2026) — lower than Zaire ebolavirus's average of 50 per cent but still among the highest CFRs of any human pathogen. Its glycoprotein, the protein surface structures that monoclonal-antibody therapies target, differs sufficiently from Zaire ebolavirus that no currently licensed treatment cross-protects against it.

Bundibugyo's low outbreak frequency before 2026 created a structural problem: limited case numbers reduced the scientific and commercial imperative to push vaccine or therapeutic candidates through clinical development. The WHO R&D Blueprint Filovirus roadmap, published in Q1 2026, formally named the non-Zaire Ebola gap three months before this outbreak emerged.

The WHO declared a PHEIC (Public Health Emergency of International Concern) for the Bundibugyo Ebola outbreak in DRC and Uganda on 17 May 2026 — the first PHEIC ever declared for this species. By that date the outbreak had recorded 8 lab-confirmed cases, 246 suspected cases and 80 suspected deaths across three health zones in Ituri Province: Bunia, Rwampara and Mongbwalu. Imperial College London's expert panel assessed that the outbreak had likely spread undetected for several weeks or months before WHO received its signal on 5 May. INRB (Institut National de Recherche Biomédicale), DRC's national reference laboratory, confirmed the species on 14 May after processing 20 samples, of which 13 were positive — a 65 per cent positivity rate consistent with uncontrolled local transmission.

The central challenge is the absence of any approved medical countermeasure. Inmazeb and Ebanga — the monoclonal-antibody therapies that transformed survival in the 2018 DRC Equateur outbreak — target Zaire ebolavirus only and have no licensed efficacy against Bundibugyo. The Ervebo vaccine, also Zaire-specific, cannot be used for ring vaccination of contacts. Clinical teams in Ituri are working with intravenous fluids, electrolyte correction, treatment of co-infections, isolation and SAFE burial: the same supportive toolkit used in 1976.

The 2026 Ituri outbreak is now the largest documented Bundibugyo outbreak on record by a factor of roughly two, and it is occurring in a geography marked by active ADF armed-group presence and gold-mining-driven population movement that complicates contact tracing and SAFE burial.